Skip to main content

Advertisement

SpringerLink
Log in

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Tumour budding is defined as the presence of isolated or small clusters of malignant cells at the invasive edge of the tumour. It is considered a negative prognostic factor in colorectal cancer (CRC) and is associated with a poor outcome and adverse pathological features. Here, we report a meta-analysis of the association of tumour budding and survival in stage II CRC patients.

Methods

PubMed, EMBASE, Web of Science and SCOPUS were searched for studies that assessed the relationship between tumour budding and 5-year overall survival (OS) in stage II CRC patients. Published data were extracted and used to compute odds ratios (ORs) for death at 5 years and hazard ratios (HRs) for survival amongst patients with respect to the extent of tumour budding, using multivariate analysis. Data were pooled using the Mantel–Haenszel random effect model.

Results

We analysed 12 studies that included a total of 1652 patients. High-grade budding was associated with worse OS at 5 years (OR for death, 6.25; 95 % confidence interval [CI], 4.04–9.67; P < 0.00001). The absolute difference in 5-year OS was −25 % (95 % CI, −18– − 33 %, P < 0.00001). It was particularly noteworthy that the presence of high-grade budding was associated with an increased risk of death (HR for death, 3.68; 95 % CI, 2.16–6.28, P < 0.00001).

Conclusions

Tumour budding is associated with worse survival in stage II CRC, in particular in pT3N0M0 patients. It could therefore potentially be used when deciding whether to administer adjuvant chemotherapy in high-risk node negative CRC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.

    Article  Google Scholar 

  2. Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg. 2012;16:646–55.

    Article  PubMed  Google Scholar 

  3. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 31 May 2014.

  4. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003;83:42–7.

    Article  PubMed  Google Scholar 

  6. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II welldifferentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003;46:1400–6.

    Article  PubMed  Google Scholar 

  7. Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51:568–72.

    Article  PubMed  Google Scholar 

  8. Yasuda K, Inomata M, Shiromizu A, et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum. 2007;50:1370–6.

    Article  PubMed  Google Scholar 

  9. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24.

    Article  CAS  PubMed  Google Scholar 

  10. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651–61.

    PubMed Central  PubMed  Google Scholar 

  11. Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63:539–43.

    Article  CAS  PubMed  Google Scholar 

  12. Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum. 2006;49:1422–30.

    Article  PubMed  Google Scholar 

  13. Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reportingsystematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer. Color Dis. 2014;16(4):259–64.

    Article  Google Scholar 

  15. Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19(12):3706–12.

    Article  PubMed  Google Scholar 

  16. Canney AL, Kevans D, Wang LM, et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding. Histopathology. 2012;61(3):488–96.

    Article  PubMed  Google Scholar 

  17. Kevans D, Wang LM, Sheahan K, et al. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Int J Surg Pathol. 2011;19(6):751–60.

    Article  CAS  PubMed  Google Scholar 

  18. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003;46(8):1054–9.

    Article  PubMed  Google Scholar 

  19. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134–41.

    Article  CAS  PubMed  Google Scholar 

  20. Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res. 2008;28(3B):1773–8.

    PubMed  Google Scholar 

  21. Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005;48(8):1597–602.

    Article  PubMed  Google Scholar 

  22. Choi HJ, Park KJ, Shin JS, et al. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Color Dis. 2007;22:863–8.

    Article  Google Scholar 

  23. Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005;25:1269–72.

    PubMed  Google Scholar 

  24. Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627–35.

    Article  CAS  PubMed  Google Scholar 

  26. Homma Y, Hamano T, Otsuki Y, et al. Severe tumor budding is a risk factor for lateral lymph node metastasis in early rectal cancers. J Surg Oncol. 2010;102:230–4.

    Article  PubMed  Google Scholar 

  27. Kajiwara Y, Ueno H, Hashiguchi Y, et al. Risk factors of nodal involvement in T2 colorectal cancer. Dis Colon Rectum. 2010;53:1393–9.

    Article  PubMed  Google Scholar 

  28. Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Color Dis. 2008;10:41–7.

    CAS  Google Scholar 

  29. Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94:293–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101:1382–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Masaki T, Matsuoka H, Sugiyama M, et al. Tumor budding and evidence-based treatment of T2 rectal carcinomas. J Surg Oncol. 2005;92:59–63.

    Article  PubMed  Google Scholar 

  32. Sohn DK, Chang HJ, Park JW, et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol. 2007;60:912–5.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94.

    Article  PubMed  Google Scholar 

  34. Ueno H, Murphy J, Jass JR, et al. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.

    Article  CAS  PubMed  Google Scholar 

  35. Ueno H, Price AB, Wilkinson KH, et al. A new prognostic staging system for rectal cancer. Ann Surg. 2004;240:832–9.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Yamauchi H, Togashi K, Kawamura YJ, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008;38:905–10.

    Article  PubMed  Google Scholar 

  37. Wang HS, Liang WY, Lin TC, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005;48:1182–92.

    Article  PubMed  Google Scholar 

  38. Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.

    PubMed  Google Scholar 

  39. Suzuki A, Togashi K, Nokubi M, et al. Evaluation of venous invasion by Elastica van Gieson stain an tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33:1601–7.

    Article  PubMed  Google Scholar 

  40. Syk E, Lenander C, Nilsson PJ, et al. Tumour budding correlates with local recurrence of rectal cancer. Color Dis. 2011;13:255–62.

    Article  CAS  Google Scholar 

  41. Bartley AN, Hamilton SR, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138(2):166–70.

    Article  PubMed  Google Scholar 

  42. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25(10):1315–25.

    Article  CAS  PubMed  Google Scholar 

  43. Koelzer VH, Zlobec I, Berger MD, et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch. 2015;21.

  44. Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697–705.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

None.

Author information

Authors and Affiliations

  1. Department of Oncology, Division of Medical Oncology, Azienda Ospedaliera Treviglio, Treviglio, BG, Italy

    F. Petrelli, M. Cabiddu, A. Coinu, K. Borgonovo, M. Ghilardi, V. Lonati & S. Barni

  2. Department of Oncology, Division of Pathology, Azienda Ospedaliera Treviglio, Treviglio, BG, Italy

    E. Pezzica & D. Corti

Authors
  1. F. Petrelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Pezzica
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Cabiddu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Coinu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Borgonovo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Ghilardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. Lonati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Corti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Barni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Petrelli.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrelli, F., Pezzica, E., Cabiddu, M. et al. Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis. J Gastrointest Canc 46, 212–218 (2015). https://doi.org/10.1007/s12029-015-9716-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9716-1

Keywords

Search

Navigation